ANI Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ANIP | AMPH | AMRX | AQST | ANIK | RDY | |
|---|---|---|---|---|---|---|
| Market cap | 1.69B | 1.14B | 6.98B | 603.71M | 273.95M | 10.68B |
| P/E (TTM) | 15.9 | 15.8 | 40.9 | — | — | 29.1 |
| Forward P/E | 7.2 | 8.4 | 16.8 | -8.4 | 21.5 | 20.0 |
| Price/book | 2.6 | 1.5 | 194.5 | -10.7 | 2.0 | 16.1 |
| Dividend yield | — | — | — | — | — | 0.67% |
| 1-year change | −17.07% | +12.15% | +106.07% | −30.09% | +115.16% | −13.09% |
| Today | −0.41% | +0.53% | +0.60% | +0.63% | +4.55% | +2.72% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All ANIP news ›ANI Pharmaceuticals reports Phase 4 eye‑implant trial met both endpoints
The uncontrolled SYNCHRONICITY study reported a 3.6-letter vision gain at six months, with improvements maintained through two years. In the United States, the Phase 4 SYNCHRONICITY eye-implant trial met both six-month endpoints in results…
ANI Pharmaceuticals Reports Positive 6- and 24-Month SYNCHRONICITY Data for ILUVIEN in Chronic NIU-PS
The SYNCHRONICITY trial demonstrated significant visual and anatomical improvements at 6 and 24 months in chronic NIU-PS patients. The trial's co-primary endpoints were mean change from baseline in BCVA letter score and mean change in CST.…
ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting
ANI Pharmaceuticals (ANIP) announced that its Phase 4 SYNCHRONICITY eye-implant trial met both primary endpoints with statistical significance at six months. The U.S. open-label, single-arm study evaluated fluocinolone acetonide…
Aphios® Corporation Appoints Dr. Juliette M. Tuakli to Board of Directors
NORTH READING, Mass.--(BUSINESS WIRE)--#Aphios--Aphios Corporation, a biotechnology company developing novel therapeutics and enabling platform technologies for significant unmet medical needs, today announced the appointment of Dr.…
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
PRINCETON, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2026. Second Quarter and…
Head to Head Contrast: ANI Pharmaceuticals (NASDAQ:ANIP) and Sunshine Biopharma (NASDAQ:SBFM)
Posted by Sarita Garza on Sep 30th, 2026 ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) and Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare…
ANI Pharmaceuticals Announces Late-Breaking AAO 2026 Presentation of Phase 4 SYNCHRONICITY Data and NEW DAY Post-Hoc Analyses | ANIP Stock News
ANI Pharmaceuticals will present findings from two clinical trials on Fluocinolone Acetonide at the AAO 2026 Meeting. The SYNCHRONICITY Trial is a Phase 4 clinical trial of Fluocinolone Acetonide Implant for chronic non-infectious uveitis…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
quiverquant.com2
-
biospace.com1
-
investor.anipharmaceuticals.com1
-
mugglehead.com1
-
themarketsdaily.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.